All In Biotech

Drug Trial Radar · NCT04129528

Study of Safety and Efficacy of CFZ533 in Type 1 Diabetes Pediatric and Young Adult Subjects

Investigator- and Subject-blinded, Randomized, Placebo-controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy Trial of CFZ533 in Pediatric and Young Adult Subjects With New Onset Type 1 Diabetes (T1DM)

Last checked: Nov 19, 2026Latest source record: Apr 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

44

Actual

Start

Nov 8, 2019

Primary completion

Jan 15, 2024

Study completion Jun 4, 2024

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Oct 16, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study was a Phase 2, multicounty, multicenter, non-confirmatory, investigator- and subject masked, randomized, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of CFZ533 on preservation of residual pancreatic β-cell function in new onset T1DM in pediatric and young adult subjects.

Conditions

  • Type 1 Diabetes Mellitus

Interventions

  • CFZ533Drug

    First dose is administered via intravenous infusion, subsequent doses are administered subcutaneously.

  • PlaceboOther

    Placebo for active drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) During the On-treatment PeriodTime frame: Adverse events were reported from first dose of study treatment to 98 days after last dose, up to a maximum duration of approximately 65 weeks.
  2. Normalized Stimulated C-peptide Area Under the Curve (AUC) at Week 52Time frame: At Week 52, 10 min prior to ingestion, at start of ingestion, and at 15, 30, 60, 90, and 120 min after consumption of the liquid meal.

Locations

12 sites in 6 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Edegem, Belgium

  • Novartis Investigative Site

    Leuven, Belgium

  • Novartis Investigative Site

    Liège, Belgium

  • Novartis Investigative Site

    Augsburg, Germany

  • Novartis Investigative Site

    Florence, FI, Italy

  • Novartis Investigative Site

    Milan, MI, Italy

  • Novartis Investigative Site

    Ljubljana, Slovenia

  • Novartis Investigative Site

    Málaga, Andalusia, Spain

  • Novartis Investigative Site

    Esplugues de Llobregat, Barcelona, Spain

  • Novartis Investigative Site

    A Coruña, Galicia, Spain

  • Novartis Investigative Site

    Nottingham, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.